Univariate outcomes
| Outcomes . | Haplo-HCT (N = 235) . | MSD HCT (N = 909) . | MUD TCD+ (N = 465) . | MUD TCD− (N = 325) . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Neutrophil recovery, 28 d | n = 230 | 86 (81-90) | n = 883 | 95 (94-97) | n = 453 | 94 (91-96) | n = 322 | 97 (94-98) | <.001 |
| Platelet recovery, 100 d | n = 219 | 80 (74-85) | n = 737 | 96 (94-97) | n = 378 | 93 (89-95) | n = 284 | 96 (93-98) | <.001 |
| Stage II-IV acute GVHD, 100 d | n = 225 | 33 (27-39) | n = 837 | 31 (28-34) | n = 429 | 30 (26-35) | n = 305 | 37 (32-42) | .03 |
| Stage III-IV acute GVHD, 100 d | n = 225 | 9 (6-13) | n = 837 | 11 (9-13) | n = 429 | 10 (8-13) | n = 305 | 18 (14-23) | .002 |
| Chronic GVHD | n = 226 | n = 770 | n = 395 | n = 296 | <.001 | ||||
| 1-y | 28 (22-34) | 41 (37-44) | 35 (30-40) | 54 (48-59) | |||||
| 2-y | 32 (25-38) | 50 (47-54) | 41 (36-46) | 64 (58-70) | |||||
| NRM | n = 237 | n = 911 | n = 468 | n = 326 | .49 | ||||
| 100 d | 11 (7-16) | 8 (7-10) | 10 (8-13) | 8 (6-12) | |||||
| 1 y | 20 (15-25) | 15 (13-18) | 18 (15-22) | 16 (13-21) | |||||
| 3 y | 22 (17-28) | 21 (18-23) | 24 (20-28) | 23 (18-28) | |||||
| Relapse | n = 237 | n = 911 | n = 468 | n = 326 | .73 | ||||
| 1 y | 22 (17-28) | 25 (22-27) | 23 (19-27) | 23 (19-28) | |||||
| 2 y | 27 (21-33) | 29 (25-32) | 26 (22-31) | 25 (20-30) | |||||
| 3 y | 28 (22-35) | 29 (26-32) | 28 (24-33) | 25 (21-30) | |||||
| PFS | n = 235 | n = 909 | n = 465 | n = 325 | .80 | ||||
| 1 y | 59 (52-65) | 61 (57-64) | 59 (54-63) | 60 (55-65) | |||||
| 3 y | 50 (43-57) | 50 (47-54) | 48 (43-53) | 52 (46-58) | |||||
| OS | n = 237 | n = 911 | n = 468 | n = 326 | .30 | ||||
| 1 y | 70 (63-75) | 74 (71-77) | 70 (65-74) | 74 (69-78) | |||||
| 3 y | 60 (52-66) | 63 (59-66) | 59 (54-64) | 64 (58-69) | |||||
| GRFS | n = 179 | n = 665 | n = 378 | n = 210 | .02 | ||||
| 1 y | 46 (38-53) | 46 (42-50) | 50 (44-55) | 38 (32-45) | |||||
| 2 y | 37 (29-45) | 36 (32-40) | 41 (36-46) | 31 (25-37) | |||||
| Outcomes . | Haplo-HCT (N = 235) . | MSD HCT (N = 909) . | MUD TCD+ (N = 465) . | MUD TCD− (N = 325) . | P . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Neutrophil recovery, 28 d | n = 230 | 86 (81-90) | n = 883 | 95 (94-97) | n = 453 | 94 (91-96) | n = 322 | 97 (94-98) | <.001 |
| Platelet recovery, 100 d | n = 219 | 80 (74-85) | n = 737 | 96 (94-97) | n = 378 | 93 (89-95) | n = 284 | 96 (93-98) | <.001 |
| Stage II-IV acute GVHD, 100 d | n = 225 | 33 (27-39) | n = 837 | 31 (28-34) | n = 429 | 30 (26-35) | n = 305 | 37 (32-42) | .03 |
| Stage III-IV acute GVHD, 100 d | n = 225 | 9 (6-13) | n = 837 | 11 (9-13) | n = 429 | 10 (8-13) | n = 305 | 18 (14-23) | .002 |
| Chronic GVHD | n = 226 | n = 770 | n = 395 | n = 296 | <.001 | ||||
| 1-y | 28 (22-34) | 41 (37-44) | 35 (30-40) | 54 (48-59) | |||||
| 2-y | 32 (25-38) | 50 (47-54) | 41 (36-46) | 64 (58-70) | |||||
| NRM | n = 237 | n = 911 | n = 468 | n = 326 | .49 | ||||
| 100 d | 11 (7-16) | 8 (7-10) | 10 (8-13) | 8 (6-12) | |||||
| 1 y | 20 (15-25) | 15 (13-18) | 18 (15-22) | 16 (13-21) | |||||
| 3 y | 22 (17-28) | 21 (18-23) | 24 (20-28) | 23 (18-28) | |||||
| Relapse | n = 237 | n = 911 | n = 468 | n = 326 | .73 | ||||
| 1 y | 22 (17-28) | 25 (22-27) | 23 (19-27) | 23 (19-28) | |||||
| 2 y | 27 (21-33) | 29 (25-32) | 26 (22-31) | 25 (20-30) | |||||
| 3 y | 28 (22-35) | 29 (26-32) | 28 (24-33) | 25 (21-30) | |||||
| PFS | n = 235 | n = 909 | n = 465 | n = 325 | .80 | ||||
| 1 y | 59 (52-65) | 61 (57-64) | 59 (54-63) | 60 (55-65) | |||||
| 3 y | 50 (43-57) | 50 (47-54) | 48 (43-53) | 52 (46-58) | |||||
| OS | n = 237 | n = 911 | n = 468 | n = 326 | .30 | ||||
| 1 y | 70 (63-75) | 74 (71-77) | 70 (65-74) | 74 (69-78) | |||||
| 3 y | 60 (52-66) | 63 (59-66) | 59 (54-64) | 64 (58-69) | |||||
| GRFS | n = 179 | n = 665 | n = 378 | n = 210 | .02 | ||||
| 1 y | 46 (38-53) | 46 (42-50) | 50 (44-55) | 38 (32-45) | |||||
| 2 y | 37 (29-45) | 36 (32-40) | 41 (36-46) | 31 (25-37) | |||||
Unless otherwise noted, all data are probability, % (95% confidence interval).